Starpharma Holdings Limited is an Australia-based company engaged in the development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. Activities within the Company are directed towards the development of nano-scale materials, with a particular focus on the development of its topical vaginal microbicide VivaGel, for the prevention of genital herpes and human immunodeficiency virus (HIV), and the application of dendrimers to drug delivery and other life science applications. The Company is also engaged in exploring dendrimer opportunities in materials science with applications in areas, such as adhesives, lubricants and water remediation. The activities are managed by the Company’s wholly owned subsidiaries, Starpharma Pty Ltd. in Melbourne and Australia, and Dendritic Nanotechnologies (DNT), Inc. in Michigan, United States. The Company has operations in Australia and United States.